Sanofi: favourable publication for Libtayo in The Lancet
(CercleFinance.com) - Sanofi has announced The Lancet's publication of data on Libtayo that shows a prolonged overall survival in patients with first-line advanced non-small cell lung cancer, in which 50% or more of the tumor cells express the PD-L1 protein.
"Libtayo was superior in extending overall survival compared to chemotherapy, even with 74% of patients crossing over to the Libtayo arm," Sanofi says, adding that this data forms the basis for regulatory submissions.
Libtayo is being jointly developed and marketed by Regeneron and Sanofi under a global collaboration agreement. Its use in the treatment of advanced NSCLC is still in a experimental phase.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"Libtayo was superior in extending overall survival compared to chemotherapy, even with 74% of patients crossing over to the Libtayo arm," Sanofi says, adding that this data forms the basis for regulatory submissions.
Libtayo is being jointly developed and marketed by Regeneron and Sanofi under a global collaboration agreement. Its use in the treatment of advanced NSCLC is still in a experimental phase.
Copyright (c) 2021 CercleFinance.com. All rights reserved.